Latest News

Europe restricts alemtuzumab use for MS


The European Medicines Agency has restricted the use of alemtuzumab (Lemtrada) for multiple sclerosis while it completes its review of safety issues that have emerged in recent months. Use of the drug will be limited to RRMS patients with highly-active disease despite prior treatment with at least two disease-modifying therapies (DMTs) or for whom all other DMTs are contraindicated. Current patients on alemtuzumab can continue taking the drug in consultation with their neurologist. Read More


Siponimod receives FDA approval for SPMS


Siponimod (Mayzent), a second-generation sphingosine-1-phosphate (S1P) receptor modulator, has received approval by the U.S. Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome (CIS), relapsing-remitting MS and active secondary-progressive MS (SPMS). Read More


Pre-AAN Survey


NeuroSens will be reporting from the American Academy of Neurology (AAN) annual meeting, with daily reports and special post-meeting coverage of key topics. Read More